Generex Biotechnology appoints Dr Yutaka Niihara to its Board of Directors as Executive Chairman

– CANADA, Burlington – Generex Biotechnology Corporation (OTC:GNBT) is pleased to announce that Dr. Yutaka Niihara, M.D., M.P.H., Chairman & Chief Executive Officer of Emmaus Life Sciences, Inc., has joined the Generex Board of Directors as its Executive Chairman.

Generex previously announced a deal to acquire a controlling equity interest in Emmaus. The Company filed a Form 8-K Current Report in respect of that acquisition with the U.S. Securities and Exchange Commission on January 20, 2017.

Dr. Niihara received his Doctor of Medicine (M.D.) degree from Loma Linda University’s School of Medicine in 1986. He completed his internship and residency at Kettering Medical Center, followed by a Hematology/Oncology Fellowship at Harbor-UCLA Medical Center. He received his Master of Public Health (M.P.H.) degree from the Harvard School of Public Health in 2006. He serves as a Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA.

Dr. Niihara is a Fellow of the American College of Physicians and a Member of the American Society of Clinical Oncology, and the American Society of Hematology. His Board Certifications include the National Board of Medical Examiners, the Japanese Medical Board, the American Board of Internal Medicine, and ABIM/Hematology. He maintains hospital affiliations at Harbor-UCLA Medical Center and the Torrance Memorial Medical Center.

Joseph Moscato, Generex President & Chief Executive Officer, commented: “We are honored to have a physician, scientist, and executive of Dr. Niihara’s comprehensive experience and noteworthy accomplishment join the Generex team. He is certain to play a pivotal role in the future successes of Generex/Emmaus.”

“It is with great anticipation that I join the new and repurposed Generex Board,” Dr. Niihara said. “I look forward to making substantial contributions, from both scientific and business perspectives, to the implementation of the Company’s strategic plans.”

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>